<u>Different modalities for the</u> <u>treatment of GEP tumors</u>

Dimitrios Linos, MD Director of Surgery, "Hygeia" Hospital, Athens, Greece Consultant in Surgery, Massachusetts General Hospital, Boston, USA

8th Postgraduate Course in Endocrine Surgery Aghia Pelaghia, Herakleion Crete 21-24 September 2006

Therapeutic modalities for GEP tumors

- Surgery
- Drugs
- Targeted radionuclide therapy
- Embolization of hepatic artery
- Radiofrequency ablation
- External radiotherapy
- Conventional chemotherapy
- Miscellaneous

Surgery

Surgery is the only treatment that provides cure

Most GEP are tumors discovered accidentally during emergency abdominal operations:

- Appendiceal carcinoid
- Small bowel carcinoid

Elective Surgery for GEP tumors

Prevention of carcinoid crisis

Gastric Carcinoids

- Type I: hypergastrinemia & chronic atrophic gastritis→<u>limited surgery</u>
- Type II:hypergastrinemia due to Z-E syndrome & MEN

I→<u>surgery</u>

• Type II: No hypergastrinemia, sporadic & more malignant→surgery

Small Bowel Carcinoids

Extensive resection of the primary lesion & associated mesenteric

lymph nodes

Nodal metastasis lead to small bowel ischemia associated with pain

& malbsorption

Colorectal carcinoids

Small lesions (<1cm) complete endoscopic removal

& follow up surveillance

Larger lesions cancer resection

& locoregional lymphadenectomy

Pancreas

- Enucleation
- Distal pancreatectomy
- Central resection
- Total pancreatectomy
- Whipple pancreatoduodenectomy
- Debulking

Primary Liver Carcinoids

Few cases

Hepatectomy

74% 5 year survival rate

18% recurrence rate

Cholecystectomy indicated

Metastatic GEP Liver lesions

"Curative"hepatic resections 10%

Debulking hepatic resections palliative

Liver Transplantation

UK Guidelines "Liver transplantation should not be

used in general"

2001 62% one year survival

23% five year survival

2002 80% five year survival

Early outcomes comparable to cirrhosis

A viable therapeutic option

Drug therapy for symptoms related to GEP tumors

- Somatostatin analogues
- Proton pump inhibitors > gastrinoma
- Diazoxid → insulinomas
- Other drugs→carcinoid syndrome
 - Ondansetron
 - Cyproheptadine
 - Pancreatic enzyme suppls.
 - Cholestrynamin
- Interepheron-alpha

The only proven hormonal management of GEP neuroendocrine tumors is the administration of somatostatin analogues

Targeted Radionuclide Therapy

- Radionuclide therapy only when there is abnormally increased uptake of the corresponding imaging agent
- 90Y-Octreotide
- Clear tumor reduction few patients
- Symptomatic improvement more frequent

MIBG

- High affinity for the noradrenalin transporter protein
- Successful treatment of carcinoid tumors with ¹³¹I-MIBG
- Symptomatic responses → 60% patients with 8 month duration of response

Embolization of hepatic artery

- Arterial embolization → ischemia of the neoplastic cells, thus reducing hormone secretion.
- Particle embolization:

Gel foam powder polyvinyl alcohol

Chemoembolization:

doxorubicin & cisplatin

Overall 5-year survival

50-60%

Mortality

4-6%

Side effects

10-17%

Post embolization syndrome

Radiofrequency Ablation (RFA)

- Metastatic lesions up to 4 cm
- As many as 20 such lesions at multiple treatment session over a period of years
- Necessary to ablate at least 90% of visible tumors

External radiotherapy

External radiotherapy is helpful in the management of pain secondary to bone metastases from carcinoid tumors.

Conventional chemotherapy

- Limited role
- cisplatin & etoposide
- Mayo Clinic study combining chemoembolization with chemotherapy → 70% response rate

Miscellaneous

- Alcohol injections
- Laser therapy
- Cryotherapy

